Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.Megan N. Thobe, Richard A. Walgren, Jessica A Baker et al.|Cancer Research|2013Cited by 3
Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitorsS. Betty Yan, Richard A. Walgren, Suzane L. Um et al.|Cancer Research|2012Cited by 1